Abstract: The present relates to interleukin 15 (IL-15) antagonists and uses thereof, in particular for the treatment of autoimmune diseases and inflammatory diseases. In particular, the present invention relates to an IL-15 mutant polypeptide having the amino acid sequence as set forth in SEQ ID NO:1 wherein the leucine residue at position 45 is substituted by an aspartic acid residue, the asparagines residue at position 65 is substituted by a lysine residue and the leucine residue at position 69 is substituted by an arginine residue.

Abstract: Disclosed is an installation for generating electricity from a heat source, for disconnecting the production of electricity from the source of heat. The main characteristic of such installation is that it includes a thermochemical storage device coupled to a power cycle, the storage device consisting of a reactor in which produces a reversible sorption process and an evaporator and a condenser, at least one of the components of the thermochemical device being coupled mass and/or thermal to at least one element of the power cycle.

Abstract: The invention relates to a genetically modified infectious measles virus derived from a live-attenuated measles virus strain, in which the gene encoding the viral accessory C protein has been knocked out (MV-deltaC). It concerns in particular the use of said genetically modified infectious MV-deltaC in the treatment of malignant tumour or cancer conditions, and for the preparation of agents or compositions for such treatment.

Abstract: Some embodiments are directed to a prognostic method for determining whether a subject is at risk of having the CLAD, comprising: measuring the expression level of POU2AF1 or BLK in a biological sample obtained from the subject; comparing the expression level of POU2AF1 or BLK with a predetermined reference value and concluding that the subject is at risk of having CLAD when the expression level of POU2AF1 or BLK is lower than the predetermined reference value.

Abstract: The invention relates to a method for predicting graft alterations in a transplanted patient, comprising a step of determining the expression levels of bactericidal/permeability-increasing protein (BPI), chemokine (C motif) ligand 1 (XCL1) and thioredoxin domain containing 3 (TXNDC3) genes in a biological sample obtained from said transplanted patient.

Abstract: A method for obtaining a population of T cells from pluripotent stem cells, which includes a first step of obtaining hematopoietic stem cells and a second step of obtaining T cells. Also, the cell populations thus obtained according to this method and these cell populations for use as a medicament.

Abstract: An artificial neuron includes a single-component electric dipole including a single material which belongs to the class of Mott insulators and is connected to first and second electric electrodes.

Abstract: The present invention relates to specific interleukin-15 (IL-15) antagonist polypeptides and uses thereof for the treatment of inflammatory and auto-immune diseases. In particular, the present invention relates to a specific interleukin-15 (IL-15) antagonist polypeptide comprising i) a IL15-Ralpha sushi-containing polypeptide comprising an amino acid sequence having at least 80% of identity with the amino acid sequence of SEQ ID NO:1 ii) a linker and iii) an IL-polypeptide comprising the amino acid sequence having at least at least 80% of identity with the amino acid sequence of SEQ ID NO:4 provided that the glutamine (Q) residue at position 108 is mutated.

Abstract: The present invention concerns a method of synthesizing a iodo- or astatoarene comprising the reaction of a diaryliodonium compound with a iodide or astatide salt, respectively. The invention also relates to said iodo- or astatoarene and diaryliodonium compound as such. The invention also concerns a method of synthesizing a iodo- or astatolabelled biomolecule and/or vector using said iodo- or astatoarene.

Abstract: Described herein are anti-CD277 antibodies which: activates or inhibit the cytolytic function of V?9/V?2 T cells, and/or costimulates T cells together with CD3-TCR, and/or costimulates T cells in addition to CD28-B7 costimulation, and/or increases the activity and/or survival of monocytes and dendritic cells. The use of said antibodies in therapy is also described.

Abstract: An antibody recognizing the O-acetylated-GD2 ganglioside for the treatment of Cancer Stem Cells (CSC) cancer, a pharmaceutical composition including the antibody for treating a CSC cancer and a method for treating a CSC cancer in a patient in need thereof, the method including administering the antibody to the patient. A method for diagnosing a CSC, the use of the O-acetylated-GD2 ganglioside as a biomarker of CSC cancer, and a method for predicting the response of a subject affected with CSC cancer to a treatment with the antibody or the composition are also described.

Abstract: A compound is provided which has dual emission properties and which is useful in light devices, and which has formula (I): wherein: A represents an electron-withdrawing group; D represents an electron-donating group; X is selected from the group consisting of: O, S and NR, wherein R is selected from the group consisting of: H, an alkyl group preferably comprising from 1 to 20 carbon atoms, an aryl group preferably comprising from 6 to 22 carbon atoms, and a heteroaryl group; n is an integer from 1 to 4; m is an integer from 1 to 6; and represents a condensed bicyclic aromatic radical comprising from 6 to 22 carbon atoms, and from 1 to 3 heteroatom(s) selected from the group consisting of: N, S and O; the OH group being in ortho position of the condensed bicyclic aromatic radical relative to the radical.

Abstract: Disclosed is a method for obtaining a population of human Treg cells including the steps of: (a) culturing a population of human monocytes with a medium including an amount of an interleukin-34 (IL-34) polypeptide in order to obtain a population of immunosuppressive macrophages; (b) co-culturing a population of human peripheral blood mononuclear cells (PBMCs) and the population of immunosuppressive macrophages obtained at step (a).

Abstract: Described herein are anti-CD277 antibodies which: activates or inhibit the cytolytic function of V?9/V?2 T cells, and/or costimulates T cells together with CD3-TCR, and/or costimulates T cells in addition to CD28-B7 costimulation, and/or increases the activity and/or survival of monocytes and dendritic cells. The use of said antibodies in therapy is also described.

Abstract: The present disclosure relates to novel anti IL-34 antibodies or antigen-binding fragments thereof specifically binding cytokine IL-34 with high affinity, the method of obtaining of these antibodies and their therapeutic use.

Abstract: The present invention concerns a method of synthesizing a iodo- or astatoarene comprising the reaction of a diaryliodonium compound with a iodide or astatide salt, respectively. The invention also relates to said iodo- or astatoarene and diaryliodonium compound as such. The invention also concerns a method of synthesizing a iodo- or astatolabelled biomolecule and/or vector using said iodo- or astatoarene.

Abstract: The present invention relates to an in vitro method for determine the prognosis of the survival time of a patient suffering from a cancer comprising the steps consisting of i) determining the expression level of the couple DNMT3A/ISGF3? in a sample from said patient, ii) comparing said expression level with a predetermined reference value and iii) providing a good prognosis when the expression level is lower than the predetermined reference value and a poor prognosis when the expression level is higher than the predetermined reference value. The invention also relates a compound which is a DNMT3A/ISGF3? antagonist or a compound which is a DNMT3A/ISGF3? gene expression inhibitor for use in the treatment and prevention of cancer.

Abstract: The present invention relates to a new lithium-doped Pernigraniline-based material, a method for the preparation thereof, its use in various applications, an electrode comprising said lithium-doped Pernigraniline-based material and its preparation method, a membrane comprising said lithium-doped Pernigraniline-based material and its preparation method, and an electrochemical storage system comprising said electrode.

Abstract: A method for reconstructing a data block of size N is proposed. The data block was encoded using an erasure code to generate a set of Ns systematic symbol vectors and a set of Np parity projection vectors from a mapping of the data block onto a two-dimensional convex support. The method comprises: for each input vector that contains at least an erasure, updating the value of each erased symbol to a predetermined value; mapping the Ns input vectors with updated values onto the two-dimensional convex support, generating a reconstruction projection vector from the mapping of the Ns input vectors with updated values onto the two-dimensional convex support using an encoding projection direction; and generating an updated parity projection vector from the reconstruction projection vector and the parity projection vector generated using said encoding projection direction.

Abstract: Device for measuring the endogenous deformations of a structure of materials, during the transition of said structure from a liquid phase to a solid phase, comprising: a uniaxial test body suitable for being embedded in the structure; a deformation measurement fiber attached to the interior of the test body; a system connected to the measurement fiber and suitable for detecting signals representative of the deformations of the measurement fiber and for determining the endogenous deformations from these signals and from known mechanical properties of the materials of the test body, the test body having a rigidity comprised between 2 and 5 gigapascals.